)
Visual
test
PMV Pharmaceuticals
PMV Pharmaceuticals (PMVP) investor relations material
PMV Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Focused on developing small molecule, tumor-agnostic therapies targeting p53 mutations, with lead candidate rezatapopt in Phase 2 clinical trials for ovarian cancer and other solid tumors.
Updated Phase 2 PYNNACLE study results for rezatapopt showed a 34% overall response rate (ORR) among 103 evaluable patients, with a median response duration of 7.6 months.
Ovarian cancer cohort achieved a 46% ORR and 8.0 months median response duration; NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.
Reported net losses of $21.1 million for Q3 2025 and $59.7 million for the nine months ended September 30, 2025, reflecting ongoing R&D investment.
No product revenue generated to date; operations funded through equity offerings and available cash.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $129.3 million as of September 30, 2025, down from $183.3 million at year-end 2024 and $148.3 million at June 30, 2025.
Research and development expenses were $18.2 million for Q3 2025 (up $1.3 million year-over-year) and $54.1 million for the nine months, mainly due to increased clinical trial costs.
General and administrative expenses decreased to $4.3 million for Q3 2025 and $12.9 million for the nine months, reflecting lower personnel, stock-based compensation, and facility costs.
Net cash used in operations was $56.4 million for the nine months ended September 30, 2025, versus $34.6 million for the same period in 2024.
Net loss per share was $(0.40) for Q3 2025 and $(1.14) for the nine months ended September 30, 2025.
Outlook and guidance
Cash runway expected to fund operations through the end of Q1 2027, based on current R&D plans.
NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer planned for Q1 2027.
Anticipates increased operating expenses as clinical development progresses and regulatory submissions approach.
Plans to complete enrollment in the ovarian cohort of the pivotal Phase 2 study by Q1 2026.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- TMCV
Q2 FY26 delivered double-digit margin growth, record cash flow, and strong market momentum. - DANSKE
Record profit, strong credit quality, and 100% payout; 2026 outlook remains positive. - GREENPLY
Q3 FY26 delivered strong revenue growth but lower profit, with major MDF expansion announced. - KRO
Q1 2025 net income surged to $18.1M on higher TiO2 sales, improved margins, and LPC integration. - WALL
Profit after tax more than tripled to SEK 2,564 million, with net asset value per share up 8%. - TMCVQ3 FY26 delivered 17% revenue growth, 12.7% EBITDA margin, and strong cash flow.
- SHL
Imaging and therapy growth drove 3.8% Q1 revenue; 2026 outlook and EPS guidance confirmed. - SAAB
Record order backlog and double-digit growth across all segments fueled strong 2025 results. - KROQ3 2025 net loss of $37M reflects lower TiO2 prices, weak demand, and higher costs.
- YATHARTH
Strong revenue and profit growth, major capital deployment, and new hospital acquisition mark the quarter.
Next PMV Pharmaceuticals earnings date
Q4 20252 Mar, 2026
PMV Pharmaceuticals
Next PMV Pharmaceuticals earnings date
Q4 20252 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
PMV Pharmaceuticals Inc. is a U.S.-based biotechnology company focused on the discovery and development of targeted therapies for cancer. The company specializes in precision oncology, aiming to create treatments that address specific genetic mutations in cancer cells. Its work spans early-stage drug discovery through clinical development. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage